Crossmark Global Holdings Inc. Has $2.86 Million Holdings in DaVita Inc. $DVA

Crossmark Global Holdings Inc. cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 17.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,166 shares of the company’s stock after selling 5,324 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $2,859,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Ethic Inc. boosted its position in DaVita by 9.2% during the 4th quarter. Ethic Inc. now owns 2,723 shares of the company’s stock worth $309,000 after acquiring an additional 229 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in shares of DaVita by 62.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 3,313 shares of the company’s stock valued at $376,000 after buying an additional 1,269 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV lifted its holdings in shares of DaVita by 10.5% during the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 2,230 shares of the company’s stock valued at $253,000 after buying an additional 212 shares during the last quarter. Intact Investment Management Inc. acquired a new stake in shares of DaVita during the 4th quarter valued at about $80,000. Finally, PFA Pension Forsikringsaktieselskab acquired a new stake in shares of DaVita during the 4th quarter valued at about $1,762,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of DVA stock opened at $198.87 on Tuesday. The stock’s 50 day simple moving average is $154.92 and its 200 day simple moving average is $133.69. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $202.13. The company has a market capitalization of $12.77 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 0.65 and a beta of 0.84.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the business earned $2.00 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DVA shares. TD Cowen lifted their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday. Truist Financial lifted their price target on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Barclays lifted their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $199.17.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.